Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.45 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3494366 | 0.87 | TEAD1 (0.50) | KDM4EALDH1A1TSHRLMNASMN1; SMN2 | |
| SCHEMBL4290686 | 0.86 | ENPP2 (0.43) | ALDH1A1ENPP2 | |
| SCHEMBL4285970 | 0.86 | KDM4E (0.51) | KDM4EALDH1A1TSHRHRH3LMNA | |
| SCHEMBL4281940 | 0.86 | KCNA5 (0.46) | ALDH1A1HRH3LMNAHTTKMT2A | |
| SCHEMBL4294643 | 0.85 | KDM4E (0.43) | KDM4EALDH1A1HRH3KMT2A | |
| SCHEMBL4289699 | 0.84 | MAOB (0.45) | ALDH1A1KMT2A | |
| SCHEMBL4292747 | 0.84 | KDM4E (0.40) | KDM4EALDH1A1TSHRHRH3MAPK1 | |
| SCHEMBL4285558 | 0.84 | HRH3 (0.45) | KDM4EALDH1A1HRH3KMT2A | |
| SCHEMBL4288979 | 0.83 | GPR183 (0.47) | KDM4EALDH1A1HRH3LMNASMN1; SMN2 | |
| SCHEMBL4286140 | 0.83 | HCRTR1 (0.44) | KDM4EALDH1A1KMT2ACYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885ALDH1A1 388/4885TP53 2535/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | KDM4E 760/4885ALDH1A1 388/4885TP53 2535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.